{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Graf SA"],"funding":["National Cancer Institute","NCI NIH HHS"],"pagination":["176-181"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7904587"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(3)"],"pubmed_abstract":["<h4>Background</h4>Histologic transformation to diffuse large B-cell lymphoma (tDLBCL) occurs in a significant proportion of indolent lymphomas. However, few studies of novel agents inform its management, particularly when relapsed after or refractory (R/R) to prior treatment.<h4>Patients and methods</h4>We prospectively evaluated ibrutinib monotherapy in pathologically documented patients with R/R tDLBCL in a single-arm study. The primary endpoint was overall response rate.<h4>Results</h4>Twenty patients who had received a median of 4 (range, 2-9) prior lines of therapy overall (median, 2.5; range, 1-9 for tDLBCL) were treated. The overall response rate was 35%, including complete responses in 15%. The median progression-free survival and overall survival were 4.1 months (95% confidence i"],"journal":["Clinical lymphoma, myeloma & leukemia"],"pubmed_title":["Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma."],"pmcid":["PMC7904587"],"funding_grant_id":["P30 CA015704","K24 CA184039"],"pubmed_authors":["Krakow E","Smith SD","Lynch RC","Kanan S","Soma L","Behnia S","Rasmussen H","Chauncey TR","Voutsinas JM","Graf SA","Wu QV","Morris K","Gopal AK","Cassaday RD"],"additional_accession":[]},"is_claimable":false,"name":"Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.","description":"<h4>Background</h4>Histologic transformation to diffuse large B-cell lymphoma (tDLBCL) occurs in a significant proportion of indolent lymphomas. However, few studies of novel agents inform its management, particularly when relapsed after or refractory (R/R) to prior treatment.<h4>Patients and methods</h4>We prospectively evaluated ibrutinib monotherapy in pathologically documented patients with R/R tDLBCL in a single-arm study. The primary endpoint was overall response rate.<h4>Results</h4>Twenty patients who had received a median of 4 (range, 2-9) prior lines of therapy overall (median, 2.5; range, 1-9 for tDLBCL) were treated. The overall response rate was 35%, including complete responses in 15%. The median progression-free survival and overall survival were 4.1 months (95% confidence i","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-05-18T12:36:35.745Z","creation":"2025-04-05T10:03:54.415Z"},"accession":"S-EPMC7904587","cross_references":{"pubmed":["33358575"],"doi":["10.1016/j.clml.2020.11.023"]}}